FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.
about
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
FV-162 is a novel, orally bioa ...... with continuous daily dosing.
@ast
FV-162 is a novel, orally bioa ...... with continuous daily dosing.
@en
type
label
FV-162 is a novel, orally bioa ...... with continuous daily dosing.
@ast
FV-162 is a novel, orally bioa ...... with continuous daily dosing.
@en
prefLabel
FV-162 is a novel, orally bioa ...... with continuous daily dosing.
@ast
FV-162 is a novel, orally bioa ...... with continuous daily dosing.
@en
P2093
P2860
P356
P1476
FV-162 is a novel, orally bioa ...... y with continuous daily dosing
@en
P2093
A Shamas-Din
P2860
P356
10.1038/CDDIS.2015.187
P577
2015-07-09T00:00:00Z